US FDA scientists point to gaps in approval, marketing

被引:0
|
作者
机构
关键词
Marketing; Prescription Drug; Health Impact; Early Warning; Adverse Health;
D O I
10.2165/00128415-200510340-00006
中图分类号
学科分类号
摘要
引用
收藏
页码:4 / 4
相关论文
共 50 条
  • [1] Withdrawing FDA Approval of Midodrine After Marketing
    Holtzman, Neil A.
    Starfield, Barbara
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2011, 305 (08): : 781 - 782
  • [2] FDA grants final marketing approval for Corlopam
    不详
    [J]. DRUG NEWS & PERSPECTIVES, 1997, 10 (08) : 482 - 482
  • [3] Summary of the US FDA Approval of Belatacept
    Archdeacon, P.
    Dixon, C.
    Belen, O.
    Albrecht, R.
    Meyer, J.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2012, 12 (03) : 554 - 562
  • [4] US scientists challenge approval of sweetener
    Woods, D
    [J]. BRITISH MEDICAL JOURNAL, 1996, 313 (7054): : 386 - 386
  • [5] Withdrawing FDA Approval of Midodrine After Marketing Reply
    Dhruva, Sanket S.
    Redberg, Rita F.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2011, 305 (08): : 782 - 782
  • [6] US FDA approval for novel darunavir formulation
    Askeland, Georgina
    [J]. FUTURE VIROLOGY, 2013, 8 (03) : 221 - 221
  • [7] SB wins US FDA approval for drug
    不详
    [J]. EUROPEAN CHEMICAL NEWS, 1996, 65 (1720): : 23 - 23
  • [8] Patient Perceptions of FDA Approval Gaps in Education or Variation in Values?
    Ford, Paul J.
    Fox, Robert J.
    Mercer, Mary Beth
    Cofield, Stacey S.
    [J]. NEUROLOGY-CLINICAL PRACTICE, 2021, 11 (04) : 273 - 279